Replies to post #75956 on Biotech Values

[DewDiligence]

I’m taking down the Genentech survey (#msg-36329285) because today’s disclosures in #msg-37028924 provide the answers about Roche’s ability to retain Genentech’s top technical people.

 
                    Old DNA         New Roche 
                    Position        Position  
 Art Levinson       CEO             Non-employee director 
 Sue Hellmann       President       Non-employee advisor 
 Richard Scheller   EVP Research    Head of embedded R&D group 
 M. Tessier-Lavigne EVP Drug Disvry CSO 
 Hal Barron         CMO             Head of oncology development 
 Andre Chan         SVP, Research   Unknown 
 Napoleone Ferrara  Fellow          Unknown

All told, 3-4 of the 6 executives in the first question of the survey will be staying on as employees, which is pretty impressive from Roche’s standpoint, IMO.

The most significant career step-up for any of Genentech’s high-ranking executives would appear to be Ian Clark (who was not part of the survey); Clark will become the head of worldwide marketing for Roche’s pharma business.

[Preciouslife1]

well, it states That Art Levinson is staying on in new role..we all figured the rest would migrate outta dodge with tens of $ millions in their saddle bags, looking to multiply
and manifest those riches into more riches elsewhere...a
new wave of biotech startups could emerge in N. California
soon....take excellent care...

Remember this: If you do not take care of your heart....

It WILL ATTACK you....

Peace,

)))PL1(((